Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CHRNG | P07510 | 1/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CHRND | Q07001 | 1/20 | 0.32 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256240 | 0.63 | CHRNB2 (0.39) | CHRNB2CHRNA7CHRNA3CHRNA4MEN1 | |
| SCHEMBL12778051 | 0.63 | CHRNB2 (0.39) | CHRNB2CHRNA7CHRNA3CHRNA4MEN1 | |
| SCHEMBL3256237 | 0.63 | CHRNB2 (0.39) | CHRNB2CHRNA7CHRNA3CHRNA4MEN1 | |
| SCHEMBL1481609 | 0.58 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA3CHRNA4MEN1 | |
| SCHEMBL30847846 | 0.58 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA3CHRNA4MEN1 | |
| Cyanide SCHEMBL27676360 | 0.58 | CHRNB2 (0.49) | CHRNB2CHRNA7CHRNA3CHRNA4MEN1 | |
| SCHEMBL15526645 | 0.57 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA3CHRNA4MEN1 | |
| SCHEMBL6979765 | 0.57 | CHRNB2 (0.41) | CHRNB2CHRNA7CHRNA3CHRNA4MEN1 | |
| SCHEMBL27578866 | 0.57 | CHRNB2 (0.47) | CHRNB2CHRNA7CHRNA3CHRNA4MEN1 | |
| SCHEMBL2409172 | 0.56 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA3CHRNA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040835-A1 | Method for Improved Use of the Production Potential of Genetically Modified Plants | BAYER CROPSCIENCE AG (DE) | 2012-02-16 | — | — | US | claimed |
| US-20120040835-A1 | Method for Improved Use of the Production Potential of Genetically Modified Plants | BAYER CROPSCIENCE AG (DE) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040835-A1 | Method for Improved Use of the Production Potential of Genetically Modified Plants | GLB1, DCXR, MT-CO2 | CHRNB2 2298/4885CHRNA7 2641/4885CHRNA3 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.